Background. The aim of this study was to compare the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus faecalis infective endocarditis (EFIE).
Enterococcus species are the third most frequent cause of infective endocarditis (IE) in developed countries, after staphylococci and streptococci, and account for 10%-14% of all IE episodes [1] [2] [3] . Enterococcus faecalis is the most frequently isolated of these microorganisms. Few contemporary studies have focused on the subgroup of patients with IE due to enterococci, and they have some limitations, such as a small sample size or retrospective design [4] [5] [6] .
International guidelines on IE recommend 4-6 weeks of penicillin or ampicillin plus an aminoglycoside for treating β-lactam-and gentamicin-susceptible enterococcal IE [7, 8] . Since the publication of an observational, nonrandomized, multicenter clinical trial in 2007 [9] , the ampicillin plus ceftriaxone (AC) combination has been recognized as a viable alternative for treating E. faecalis IE (EFIE) caused by isolates with highlevel aminoglycoside resistance (HLAR) [8] . In daily practice, this combination has also been used for treating non-HLAR EFIE. There are, however, no studies comparing AC and ampicillin plus gentamicin (AG) for treating EFIE. Thus, the aim of this study was to compare the safety and effectiveness of these 2 antimicrobial combinations for treating this disease.
METHODS

Design, Settings, and Patients
This observational, nonrandomized, comparative multicenter cohort study was performed at 17 hospitals located in 5 different geographical areas of Spain, and 1 center in Rome, Italy. All but 3 of the Spanish centers were referral hospitals for cardiac surgery.
All consecutive adult patients (≥18 years of age) with a diagnosis of EFIE treated from January 2005 through December 2011 were enrolled in the study. Patients were prospectively identified from the Infectious Diseases, Internal Medicine, Neurology, Cardiology, and Cardiac Surgery (when present) departments, the Microbiology Department's blood culture registry, and the Echocardiography Laboratory of each participating hospital. All patients in each center were evaluated by the same staff medical team during the entire study period.
Definitions
IE was defined as definite or possible according to the modified Duke criteria [10] . Healthcare-associated IE [11] and catheter-related bacteremia [12] have been defined elsewhere. The Charlson comorbidity index [13] was used at admission to stratify overall comorbidity. The indication for surgery was established according to current guidelines [7, 8] .
Right-sided IE was defined as isolated infection of the tricuspid or pulmonary valves without involvement of the leftsided valves or any implantable cardiac device. Prosthetic valve IE was defined as involvement of at least 1 prosthetic valve, regardless of the presence of infection in the other native valves. Pacemaker IE was defined as lead infection plus endocardial involvement.
We classified a patient as having received AC or AG if, once the etiology of IE was known, a 4-to 6-week course was planned with any of these antimicrobial combinations (for AG, at least 2 weeks of planned gentamicin [14] ) and oral antimicrobial suppressive therapy was not administered at the end of this time period. Otherwise, patients were classified as having received other antimicrobial therapies. Three patients receiving penicillin plus gentamicin were assigned to the AG group.
Ampicillin was administered intravenously at 2 g every 4 hours (adjusted according to renal function when necessary), ceftriaxone intravenously at 2 g every 12 hours, and gentamicin at 3 mg/kg/day (adjusted according to renal function when necessary). Gentamicin was administered in 1, 2, or 3 divided doses according to the criteria of the attending physician and renal function at diagnosis. Use of AC, AG, or other antibiotic combinations was decided by the attending physician based on local protocols. Gentamicin trough levels were monitored in the referral centers according to local protocols, with a target of 0.5-1 mg/L for multidose administration.
IE complications were defined as the development of any of the following conditions: (1) congestive heart failure (new condition or worsening of a known condition), (2) paravalvular complication (diagnosed by echocardiography or during surgery), (3) stroke, (4) symptomatic systemic embolism other than stroke, and (5) acute renal failure, established as a 25% increase in the baseline creatinine concentration.
Outcomes
Adverse effects recorded in patients receiving AC and AG included leukopenia (total white blood cell count <4000 cells/ mm 3 ), fever (axillar temperature ≥38.3°C), new renal failure (defined above), and vestibular toxicity. These were considered adverse effects after excluding other potential causes, such as uncontrolled infection. Interruption of antimicrobial treatment due to adverse events was left to the physician's criteria.
Treatment failure requiring a change of antimicrobials was defined as a change of antimicrobial therapy based on detection of new vegetations, septic paravalvular complications, or persistently positive blood cultures to E. faecalis in a patient still undergoing treatment.
Mortality was defined as death from any cause while on antimicrobial treatment or up to 3 months of follow-up. Follow-up was defined as the period between the day after completing antimicrobial therapy to death or the last clinical control. A minimum of 3 months' follow-up was required in each case. Relapse was established on documentation of positive blood cultures caused by the same microorganism as the initial endocarditis within the first 3 months after completing antimicrobial treatment.
Data Collection
Demographic, clinical, treatment, and follow-up data were obtained by detailed chart abstraction with use of standardized reporting forms and were entered in a database created specifically for the purposes of the study (Microsoft Access 2000).
Starting in October 2010, data were prospectively collected in 14 hospitals. Before that time, and for the entire study period in the remaining 4 hospitals, data were retrospectively collected. Nonetheless, all centers have broad experience in treating IE patients and consolidated IE databases in which the information is prospectively collected. This study was conducted with the approval of the ethics committees of all the participating centers, and informed consent from patients was not required.
Statistical Analysis
Quantitative variables are reported as the median (interquartile range [IQR]), and qualitative variables are reported as percentages. The χ 2 test was used to compare the distribution of categorical variables, and the Student t test for comparison of continuous variables. For variables with a nonnormal distribution, we used the Mann-Whitney test. Differences were considered statistically significant at a P value of <.05. All outcomes were estimated using an intent-to treat analysis. All tests were 2-sided, with a 95% confidence interval. Statistical analyses were performed with SPSS-PC+, version 15.0 (SPSS, Chicago, Illinois).
RESULTS
Epidemiological, Clinical, and Outcome Characteristics of the Complete EFIE Series
During the study period, 291 episodes of EFIE were treated in 291 patients: 159 (55%) with AC, 87 (30%) with AG, and 45 (15%) with other antimicrobial combinations. Among the total, 272 (94%) episodes were diagnosed as definite IE according to the modified Duke criteria. Seventy-two (25%) E. faecalis strains showed HLAR. Overall, EFIE patients had a median age of 69.9 years (IQR, 60.1-76.6 years), and 206 (71%) were men. The median score on the Charlson index was 2 points (IQR, 1-4 points). Ninety-eight patients (34%) had diabetes mellitus, 85 (29%) chronic renal failure (21 of them undergoing hemodialysis), 42 (14%) cancer, and 21 (7%) liver cirrhosis; 10 (3%) were transplant recipients, and 10 (3%) had HIV infection. One hundred fifty-two (52%) patients acquired the infection in the healthcare setting. The known origins of infection were urologic (80 [28%]), catheter-related bacteremia (37 [13%]), gastrointestinal (34 [12%]), previous cardiac surgery (19 [7%] ), and others (17 [6%] ). In 104 (36%) patients, the source of infection could not be identified.
EFIE affected native valves in 186 (64%) cases, prosthetic valves in 102 (35%), and implanted cardiac devices in 3 (1%). Eleven (4%) episodes were exclusively right-sided.
The median interval from symptoms onset to the start of antimicrobial treatment was 16 days (IQR, 5-44 days). At least 1 complication was diagnosed in 226 (78%) patients; 166 (57%) had congestive heart failure, 106 (36%) acute renal failure, 65 (22%) septic paravalvular complications, 49 (17%) symptomatic embolisms other than stroke, and 45 (16%) stroke.
Surgery was indicated in 174 (60%) cases, with the most common indications being refractory heart failure (112/174 [64%]) and septic paravalvular complication (54/174 [31%]). However, surgery was ultimately performed in only 104 of 174 (60%) cases, a median of 10 days (IQR, 4-22 days) after the start of treatment. In 89 of 104 (86%) patients, valve culture was carried out. The median duration of treatment before surgery was 22 days in the 39 patients with negative valve culture (IQR, 10-38 days), and 8 days (IQR, 3-15 days) in the 50 patients with positive valve culture (P < .001).
In the total series, 224 (77%) patients remained alive at the end of antimicrobial treatment, after a median of 42 days (IQR, 37-45 days) of antibiotics, and 212 (73%) patients remained alive at discharge. Median follow-up was 11.1 months (IQR, 4.4-22.5 months) in the 224 patients alive at the end of antimicrobial therapy. During that time period, 10 patients (5%) relapsed at a median of 37 days (IQR, 25-55 days) after completing antimicrobial treatment, and 12 patients (5%) underwent surgery at a median follow-up of 78 days (IQR, 48-109 days) after completion of antimicrobial treatment.
Comparative Findings in the AC Versus AG Treatment Groups
The demographic and clinical features of 246 EFIE episodes treated with AC (n = 159) or AG (n = 87) are shown in Table 1 . In 51 (32%) episodes of EFIE treated with AC, the causal strains showed HLAR. The 2 treatment groups were comparable, except for the fact that AC patients had a greater incidence of chronic renal failure (33% vs 16%, P = .004), neoplastic disease (18% vs 7%, P = .015), transplantation (6% vs 0%, P = .040), and infection acquired in the healthcare setting (59% vs 40%, P = .006).
The antimicrobial treatment received, complications, surgeries, and in-hospital mortality of the 2 treatment groups is shown in Table 2 . Of note, patients in the AG group presented new renal failure more often than did AC patients (46% vs 33%, P = .051).
Last, the outcomes of patients treated with the AC or AG combinations are summarized in Table 3 . Between AC-and AG-treated EFIE patients, there were no differences in mortality while on antimicrobial treatment (22% vs 21%, P = .81), mortality at 3 months of follow-up (8% vs 7%, P = .72), treatment failure requiring an antimicrobial change (1% vs 2%, P = .54), or relapse (3% vs 4%, P = .67). However, AG had to be discontinued much more often than AC owing to adverse events (25% vs 1%, P < .001), mainly new renal failure (23% vs 0%, P < .001).
In the comparisons of the subgroup of patients with EFIE caused by non-HLAR strains (108 patients treated with AC and 87 patients treated with AG), similar results were found (data not shown). The only difference was a higher percentage of patients with septic paravalvular complications in the AC group (40% vs 26%, P = .050).
Gentamicin Use in Patients With EFIE Caused by Non-HLAR Strains
In 31 patients, gentamicin was administered as long as ampicillin. In 34 patients (39%), gentamicin was stopped before completing antimicrobial treatment as had been previously 15 days [IQR, 7-17 days]), AG was switched to daptomycin in 1 patient after 14 days, and AG was switched to linezolid plus levofloxacin in the last patient after 10 days. Monitoring of gentamicin plasma levels was performed in 52 of 87 patients (60%). In 80 patients (92%), data on gentamicin administration schedule were obtained. In 37 patients, gentamicin was administered once a day, in 6 twice a day, and in 37 three times a day.
DISCUSSION
In this observational, nonrandomized, comparative multicenter cohort study, the AC combination was as effective as AG for treating E. faecalis infective endocarditis. Although ACtreated patients in the present series were in poorer general condition before acquiring the infection than AG patients, there were no differences in mortality between the treatment groups. However, AG patients experienced a high rate of adverse events related to antimicrobial therapy and, for this reason, antibiotics had to be withdrawn in 25% of cases.
To our knowledge, this is the most extensive published report on EFIE to date, including a large number of reference centers, a fact that lends strength to the results. Although E. faecalis is now the third most frequent cause of IE [1] [2] [3] , there are few contemporary studies on this subject. This lack of findings is particularly important because of the continuous epidemiologic changes IE has undergone over the last few years [15] . It is noteworthy that >50% of patients in the present study acquired the infection by close contact with the healthcare system. The nosocomial origin of a considerable percentage of enterococcal bacteremia and endocarditis cases has been pointed out by Fernández-Guerrero et al [5, 16] . In consequence, the median age in this cohort of patients and the percentage of previous comorbid conditions is particularly high, in keeping with findings from previous studies [4] [5] [6] 14] .
The lack of comparative clinical studies on antimicrobial therapy for EFIE has prompted various in vitro and animal experiments to be carried out with several antimicrobial combinations [17] [18] [19] [20] [21] . In one recently published study, gentamicin proved to be the most effective aminoglycoside for treating EFIE in a rabbit model, with best efficacy at 6 mg/kg/day [21] . Nonetheless, bearing in mind that EFIE often affects frail elderly patients with, or at risk of, renal failure, the recommendation of 4-6 weeks of penicillin or ampicillin plus an aminoglycoside for treating β-lactam-and gentamicin-susceptible enterococcal IE is a matter of concern. This situation has motivated publication of a study evaluating the length of aminoglycoside administration for this purpose, in which it was concluded that 2-3 weeks of aminoglycoside treatment might suffice [14] .
Since publication of an observational, nonrandomized, multicenter clinical trial in this line [9] , the AC combination has been recognized as an alternative for treating EFIE due to HLAR isolates [8] . However, this combination can be used in both HLAR and non-HLAR EFIE, and administration of these agents is neither limited by, nor a cause of, renal failure. Although the present study was not a randomized trial, AC proved to be as effective as AG, even though patients treated with this combination were in a poorer general condition at baseline ( prior to acquiring the infection) than patients in the AG group. Moreover, acute renal failure occurred more frequently in patients receiving gentamicin. However, AC can be used with no risk of renal failure and regardless of the HLAR status of E. faecalis.
In our study, relapse occurred in 5% of all EFIE cases, 3% in the AC group, and 4% in AG-treated patients. The relapse rate for the overall series was similar to the reported rate of 7% of relapses in a retrospective Spanish study [5] of 47 episodes of EFIE, but far from the 0% reported by Wilson et al in 1984 [22] . However, both studies are not comparable owing to the relevant changes in the epidemiology this disease has suffered in the last decades [1, 15] . Focusing on patients treated with AC, our previous study showed a relapse risk of 5% [9] . Although the information about relapses in recent studies is scarce, a recent report described 2% of relapses in a general contemporary series of left-sided infective endocarditis [1] . The present study has several limitations, the most important being retrospective collection of many of the cases. However, all the participating centers have extensive experience in managing IE patients and all maintain local databases with prospectively collected, standard variables, and our previous experience has proven that the populations are comparable. Second, although it is a comparative study, it was not randomized because the use of different antimicrobial combinations for treating EFIE was center-dependent. Some hospitals always use AC in EFIE; others administer AG for non-HLAR and AC for HLAR EFIE; and, in the remaining centers, the choice between AC and AG treatment depends on the baseline renal function and/or the risk of new renal failure. Thus, there may have been some selection bias, in which patients in poorer clinical condition at baseline would be included in the AC group, as evidenced in the overall series by a higher percentage of patients with chronic renal failure receiving this treatment (33% vs 16%, P = .004) and in the non-HLAR subgroup by a higher percentage of septic paravalvular complications in patients receiving AC (40% vs 26%, P = .050). Third, due to its observational, nonrandomized nature, interruption of gentamicin due to adverse events was left to the discretion of the attending physician. Moreover, gentamicin levels were not determined in all centers because this technique was not available in the few participating community hospitals. These factors may have introduced some bias in the study toward significantly greater toxicity in the AG group. Nonetheless, these considerations also highlight the difficulties encountered when treating E. faecalis IE with gentamicin in actual clinical practice: it can be a difficult antimicrobial to manage, especially in patients with some degree of renal failure at the start of treatment. Another limitation of this multicenter study is the lack of molecular analysis of E. faecalis strains, because of which it was unknown whether there was a clonal cluster of cases in patients with healthcare-associated acquisition. Finally, the relatively small sample of non-HLAR EFIE patients treated with AG limited the statistical power of some of the comparisons with AC-treated non-HLAR EFIE patients.
In conclusion, in our cohort of E. faecalis infective endocarditis patients, treatment with the AC combination was found to be as therapeutically similar to treatment with AG. However, discontinuation of AG was often required because of acute renal failure. AC can be used with no risk of renal failure and regardless of the HLAR status of E. faecalis. A randomized controlled trial should be performed to further confirm these observations.
Notes
